CAMP
CAMPHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeCamp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. The company carries a $207.1M market cap, placing it firmly in the micro-cap category. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders.
Market Cap
$207.1M
Beta
0.26
P/E (TTM)
—
P/E (Fwd)
-3.86
EPS (TTM)
$-2.32
EPS (Fwd)
$-0.85
ROE
-545.9%
ROA
-45.3%
Cash
$86.4M
Total Debt
$2.4M
Free CF
-$12.8M
52W Change
-11.3%
Annual Financials
Cash vs Debt
Where CAMP stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, CAMP finished 25.24% below its 150-day moving average ($4.20) and 27.48% below its 200-day moving average ($4.33). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CAMP overbought or oversold?
At the October 20, 2026 close, CAMP's RSI(14) was 25.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $86.4M in cash comfortably exceeding the $2.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$12.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -545.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
CAMP's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. With cash comfortably exceeding debt, CAMP has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for CAMP and its sector.